Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Rises By 177.1%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 16,388 shares, an increase of 177.1% from the May 14th total of 5,914 shares. Based on an average daily volume of 8,366 shares, the short-interest ratio is presently 2.0 days. Currently, 0.8% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC acquired a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Stock Up 7.3%

Shares of XBIO traded up $0.22 during midday trading on Friday, reaching $3.22. The company had a trading volume of 14,546 shares, compared to its average volume of 20,483. Xenetic Biosciences has a 1-year low of $1.90 and a 1-year high of $13.93. The stock has a market cap of $7.37 million, a PE ratio of -2.70 and a beta of 2.19. The firm has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $2.66.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $0.81 million for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.